LUPIN informs about press release

23 Jun 2023 Evaluate
LUPIN has informed that it enclosed a Press release regarding launch of Rufinamide Oral Suspension, 40 mg/mL to market a generic equivalent of Banzel Oral Suspension, 40 mg/mL of Eisai Inc. This is disclosure pursuant to Regulation 30 of the Listing Regulations.

The above information is a part of company’s filings submitted to BSE.

Peers
Company Name CMP
ICICINXT50 63.66
EMAMILTD7 423.00
TGV Securities
Arihant Mangal Scheme
PropShare Celestia
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×